A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes

Carregando...
Imagem de Miniatura
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
TERMEDIA PUBLISHING HOUSE LTD
Citação
CLINICAL AND EXPERIMENTAL HEPATOLOGY, v.8, n.1, p.42-48, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aim of the study: Hepatocellular carcinoma (HCC) is a lethal malignancy with heterogeneous behavior determined by liver function, clinical presentation and treatment response. Peritoneal metastasis (PM) from HCC is rare and management is challenging. We aim to report a cohort of patients with advanced HCC and describe demographic characteristics, treatment and outcomes of patients with PM. Material and methods: We analyzed data from a retrospective cohort of patients with HCC. Patients with PM were analyzed individually. Baseline characteristics, treatment strategy and median overall survival (OS) with 95% confidence interval (CI) were reported. Results: 238 patients with advanced HCC were evaluated. Eleven patients had PM: 7 patients were treated with systemic treatment and 4 were treated with upfront peritonectomy followed by systemic treatment at recurrence. These 4 patients had well-preserved liver function and low disease burden and were younger compared to the total cohort. The median time to recurrence after peritonectomy was 30.25 months (interquartile range [IQR]: 13.53-46.92): 3 of them presented peritoneal recurrence (2 with diffuse peritoneal spread and 1 with concomitant hepatic recurrence) and 1 presented pulmonary recurrence. Overall, patients with PM showed similar OS compared to patients with other metastatic sites (11.8 months; 95% CI: 1.5-19.8 vs. 8 months; 95% CI: 6.7-10, p = 0.901). Patients with PM treated with upfront surgery had a median OS of 60 months (95% CI: 16.7-not reached). Conclusions: Resection of PM from HCC may provide long-term survival in selected patients. A multidisciplinary approach is the optimal strategy for managing PM from HCC.
Palavras-chave
hepatocellular carcinoma, peritonectomy, liver cancer, prognosis, cancer treatment
Referências
  1. Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
  2. Bruix J, 2019, NAT REV GASTRO HEPAT, V16, P617, DOI 10.1038/s41575-019-0179-x
  3. Chua TC, 2012, SURG ONCOL, V21, P95, DOI 10.1016/j.suronc.2011.01.005
  4. Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745
  5. Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
  6. Gordan JD, 2020, J CLIN ONCOL, V38, P4317, DOI 10.1200/JCO.20.02672
  7. Honore C, 2016, J VISC SURG, V153, P101, DOI 10.1016/j.jviscsurg.2015.11.010
  8. Jacquet P, 1996, Cancer Treat Res, V82, P359
  9. Kosaka A, 1999, SURG TODAY, V29, P453, DOI 10.1007/BF02483040
  10. Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1
  11. Kwak MS, 2012, DIGEST DIS SCI, V57, P813, DOI 10.1007/s10620-011-1995-1
  12. Lin CC, 2009, J GASTROEN HEPATOL, V24, P815, DOI 10.1111/j.1440-1746.2009.05848.x
  13. Llovet JM, 2003, J HEPATOL, V38, pS136, DOI 10.1016/S0168-8278(02)00432-4
  14. Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
  15. Natsuizaka M, 2005, J GASTROEN HEPATOL, V20, P1781, DOI 10.1111/j.1440-1746.2005.03919.x
  16. Reig M, 2018, J HEPATOL, V69, P525, DOI 10.1016/j.jhep.2018.03.028
  17. Ren A, 2019, ASIAN J SURG, V42, P464, DOI 10.1016/j.asjsur.2018.09.006
  18. Sarveazad A, 2019, J RES MED SCI, V24, DOI 10.4103/jrms.JRMS_1017_18
  19. Stigliano R, 2007, CANCER TREAT REV, V33, P437, DOI 10.1016/j.ctrv.2007.04.001
  20. Tabrizian P, 2014, J SURG ONCOL, V110, P786, DOI 10.1002/jso.23739
  21. Uchino K, 2011, CANCER-AM CANCER SOC, V117, P4475, DOI 10.1002/cncr.25960
  22. Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263
  23. Yeh CN, 2004, WORLD J SURG, V28, P382, DOI 10.1007/s00268-003-7319-7